Atherosclerosis, characterized by the formation of fat-laden plaques, is a chronic inflammatory disease. ABCA1 promotes cholesterol efflux, reduces cellular cholesterol accumulation, and regulates anti-inflammatory activities in an apoA-I- or ANXA1-dependent manner. The latter activity occurs by mediating the efflux of ANXA1, which plays a critical role in anti-inflammatory effects, cholesterol transport, exosome and microparticle secretion, and apoptotic cell clearance. ANXA1 Protein, Human, Recombinant (His) is expressed in E. coli expression system with C-His tag. The predicted molecular weight is 39.5 kDa and the accession number is P04083.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
100 μg | 約5 days | ¥ 85,500 |
500 μg | 約5 days | ¥ 342,000 |
1 mg | 約5 days | ¥ 569,500 |
説明 | Atherosclerosis, characterized by the formation of fat-laden plaques, is a chronic inflammatory disease. ABCA1 promotes cholesterol efflux, reduces cellular cholesterol accumulation, and regulates anti-inflammatory activities in an apoA-I- or ANXA1-dependent manner. The latter activity occurs by mediating the efflux of ANXA1, which plays a critical role in anti-inflammatory effects, cholesterol transport, exosome and microparticle secretion, and apoptotic cell clearance. ANXA1 Protein, Human, Recombinant (His) is expressed in E. coli expression system with C-His tag. The predicted molecular weight is 39.5 kDa and the accession number is P04083. |
Species | Human |
Expression Host | E. coli |
Tag | C-His |
Accession Number | P04083 |
別名 | Annexin A1, Calpactin II, ANX1, p35, Lipocortin I, ANXA1, Calpactin-2, Annexin I, LPC1, Chromobindin-9, Annexin-1 |
Construction | Met1-Asn346 |
Protein Purity | > 95% as determined by Tris-Bis PAGE |
分子量 | 39.5 kDa (predicted) same as Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. |
Research Background | Atherosclerosis, characterized by the formation of fat-laden plaques, is a chronic inflammatory disease. ABCA1 promotes cholesterol efflux, reduces cellular cholesterol accumulation, and regulates anti-inflammatory activities in an apoA-I- or ANXA1-dependent manner. The latter activity occurs by mediating the efflux of ANXA1, which plays a critical role in anti-inflammatory effects, cholesterol transport, exosome and microparticle secretion, and apoptotic cell clearance. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
ANXA1 Protein, Human, Recombinant (His) ANX-1 Annexin A1 Calpactin II ANX1 p35 Lipocortin I ANXA1 ANXA 1 Calpactin-2 LPC-1 Annexin I LPC 1 LPC1 ANXA-1 Chromobindin-9 Annexin-1 ANX 1 recombinant recombinant-proteins proteins protein